Compounding Law: How Many “Outsourcing Facilities” Will Emerge?
This article was originally published in The Pink Sheet Daily
As bill heads to President, voluntary registration system for compounders likely means not all large-scale operations will subject themselves to FDA oversight.
You may also be interested in...
Pharmacy benefit manager's anti-Daraprim effort signals new direction in pricing battles, but the strategy can only be used in limited circumstances.
State regulators seem to agree with FDA about confusion over regulatory responsibility, saying writing consistent definitions for compounding and manufacturing will help determine future FDA involvement.
After the House and Senate question whether FDA needs more authority to regulate compounders like the New England Compounding Center, Sen. Lamar Alexander suggests clearly designating who has jurisdiction may be the answer.